BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

InnoCentive, Inc. Announces Further Expansion Into The Pharmaceutical And Chemical Industries With The Addition Of Two Major Clients To Its Global Scientific R&D Platform


10/19/2005 5:08:42 PM

ANDOVER, Mass., June 6 /PRNewswire/ -- InnoCentive today announced Ciba Specialty Chemicals and Novartis Pharma AG have joined its online scientific forum, a global community where world-class companies and scientists collaborate to solve research and development challenges. As the latest members of InnoCentive's fast growing clientele of Seekers, they will have the opportunity to increase their R&D potential and significantly enhance their current research initiatives by tapping into the expertise of some of the world's top scientific minds.

"We are delighted that global leaders such as Ciba Specialty Chemicals and Novartis Pharma AG have chosen InnoCentive's online network for scientific R&D collaboration," said Darren J. Carroll, CEO, InnoCentive. "We look forward to working with them and contributing to their success in delivering cutting-edge solutions to customers."

"Through InnoCentive, Ciba Specialty Chemicals will be able to significantly enhance its current R&D initiatives," said Dr. Werner Rutsch, head, Corporate Technology Office, Ciba Specialty Chemicals. "InnoCentive's community of Solvers will add a new dimension of creativity to our research efforts."

Through a confidential website, www.innocentive.com, Seeker companies post their challenges to more than 80,000 scientists, researchers and scientific organizations located in more than 175 countries worldwide. Scientists who deliver solutions that best meet InnoCentive's challenge requirements receive a financial award ranging up to USD$100,000.

"InnoCentive continues to connect leading companies to the brightest scientists in the world's most vibrant markets, including China, India, and Russia. Our online global forum is expanding rapidly, and we are thrilled that corporations like Boeing, Ciba, Dow, DuPont, Eli Lilly and Company, Novartis Pharma AG, and Procter & Gamble, are able to leverage this talented pool of scientists to augment their research and development initiatives," said Ali Hussein, vice president of marketing, InnoCentive. "We are committed to helping global corporations solve their most difficult challenges more efficiently."

In addition to the newly established relationships with Ciba and Novartis, InnoCentive recently renewed its contract with Dow. "Dow is committed to bringing innovations to market in a timely fashion," said Dr. Dan Kittle, vice president of R&D for The Dow Chemical Company. "Our relationship with InnoCentive gives us access to an unparalleled global community of scientists. We renewed our contract with InnoCentive because it has accelerated the pace of our R&D innovation by fostering scientific collaboration that crosses traditional boundaries."

"InnoCentive continues to expand its Seeker clients by adding global blue-chip companies," said Cesar Castro, vice president of business development, InnoCentive. "This renewed agreement by one of our earliest signed companies, Dow, attests to the success and viability of InnoCentive's mission to address the growing R&D challenges globally. InnoCentive was founded to extend research beyond traditional boundaries and our rapidly expanding network of Seeker companies which now includes Ciba and Novartis Pharma AG reflects this commitment."

About Ciba Specialty Chemicals

Ciba Specialty Chemicals is a leading global company dedicated to producing high-value effects for its customers' products. We strive to be the partner of choice for our customers, offering them innovative products and one-stop expert service. We create effects that improve the quality of life -- adding performance, protection, color and strength to textiles, plastics, paper, automobiles, buildings, home and personal care products and much more. Ciba Specialty Chemicals is active in more than 120 countries around the world and is committed to be a leader in its chosen markets. In 2004, the Company generated sales of 7 billion Swiss francs and invested 288 million in R&D.

About Dow

Dow is a leader in science and technology, providing innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $40 billion, Dow serves customers in 175 countries and a wide range of markets that are vital to human progress: food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of sustainable development, Dow and its 43,000 employees seek to balance economic, environmental and social responsibilities. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted.

About InnoCentive

InnoCentive is the first online forum that allows world-class scientists and science-based companies to collaborate in a global scientific community to achieve innovative solutions to complex challenges. InnoCentive is an e-business venture of Eli Lilly and Company, a leading innovation-driven pharmaceutical company. To learn more, visit the InnoCentive Web site at www.innocentive.com.

For More Information: Tara Bal Media Contact for InnoCentive 510-226-6780 x 162 innocentive-pr@e21corp.com

InnoCentive

CONTACT: Tara Bal, +1-510-226-6780, ext. 162, orinnocentive-pr@e21corp.com, for InnoCentive


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->